Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M109165200 on December 18, 2001

J. Biol. Chem., Vol. 277, Issue 10, 8673-8681, March 8, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/10/8673    most recent
M109165200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, K. B.
Right arrow Articles by Carter-Su, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, K. B.
Right arrow Articles by Carter-Su, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

SH2-B Family Members Differentially Regulate JAK Family Tyrosine Kinases*

Karen B. O'BrienDagger §, John J. O'Shea, and Christin Carter-SuDagger ||

From the Dagger  Department of Physiology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0622 and  NIAMS, National Institutes of Health, Bethesda, Maryland 28092-1820

Received for publication, September 21, 2001, and in revised form, December 12, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Activation of JAK tyrosine kinases is an essential step in cell signaling by multiple hormones, cytokines, and growth factors, including growth hormone (GH) and interferon-gamma . Previously, we identified SH2-Bbeta as a potent activator of JAK2 (Rui, L., and Carter-Su, C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7172-7177). Here, we investigated whether the activation of JAK2 by SH2-Bbeta is specific to JAK2 and SH2-Bbeta or extends to other JAKs or other members of the SH2-Bbeta family. When SH2-Bbeta was overexpressed with JAK1 or JAK3, SH2-Bbeta failed to increase their activity. However, SH2-Bbeta bound to both and was tyrosyl-phosphorylated by JAK1. In contrast to SH2-Bbeta , APS decreased tyrosyl phosphorylation of GH-stimulated JAK2 as well as Stat5B, a substrate of JAK2. APS also decreased tyrosyl phosphorylation of JAK1, but did not affect the activity or tyrosyl phosphorylation of JAK3. Overexpressed APS bound to and was tyrosyl-phosphorylated by all three JAKs. Consistent with these data, in 3T3-F442A adipocytes, endogenous APS was tyrosyl-phosphorylated in response to GH and interferon-gamma . These results suggest that 1) SH2-Bbeta specifically activates JAK2, 2) APS negatively regulates both JAK2 and JAK1, and 3) both SH2-Bbeta and APS may serve as adapter proteins for all three JAKs independent of any role they have in JAK activity.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Janus family tyrosine kinases, consisting of JAK1,1 JAK2, JAK3, and Tyk2, bind to members of the cytokine family of receptors and are activated upon ligand binding to these receptors. This family of receptors consists of more than 20 different proteins that are known to bind to at least 25 different ligands, including growth hormone (GH), prolactin, leptin, interferon (IFN)-alpha , IFN-beta , IFN-gamma , and most interleukins (1, 2). Of these 25 ligands, more than two-thirds activate JAK2. JAK1 and Tyk2, like JAK2, are ubiquitously expressed and, in general, are activated by a similar, although more limited set of ligands compared with JAK2. In contrast, JAK3 is predominantly expressed in hematopoietic cells and is activated by a different set of ligands, including interleukin (IL)-2, IL-4, and IL-7, which are not potent activators of JAK2 (2, 3). Knockout studies have revealed specific and vital roles for JAK kinases. Mice deficient in JAK2 die by day 12 of embryogenesis from a lack of erythropoiesis (4, 5). JAK1-deficient mice are smaller than their littermates, fail to nurse, and die within 1 day of birth (6). In contrast to JAK1- or JAK2-deficient mice, JAK3 knockout mice survive and develop normally in pathogen-free conditions. However, these mice exhibit severe defects in lymphoid development (7-9). Mice lacking Tyk2 develop normally and exhibit no major abnormalities in fertility or blood cell development. However, Tyk2-deficient mice have reduced responses to specific cytokines, including IFN-alpha /beta , IL-12, and IFN-gamma (10). Taken together, studies using cellular models as well as analysis of knockout mice show that activation of JAKs is critical for such diverse responses as growth, lactation, nerve cell differentiation, hematopoiesis, and immune responses (3, 10-12).

Upon ligand binding to cytokine receptors, JAKs phosphorylate themselves and their associated receptors, thereby providing multiple binding sites for signaling proteins containing SH2 or other phosphotyrosine-binding domains. Signaling proteins that bind to receptor·JAK complexes and undergo tyrosyl phosphorylation include STATs (13), Shc (14), insulin receptor substrates (15, 16), and focal adhesion kinase (17). Although activation of JAKs by cytokine receptor ligands is generally rapid and transient, constitutive activation of JAKs has been observed in a variety of cancers, indicating that regulation of JAKs is critical for controlling cell growth and proliferation. For example, leukemic cells from patients with acute lymphoblastic leukemia (18) were shown to have constitutively active JAK2, and specific inhibition of JAK2 in cells derived from an acute lymphoblastic leukemia patient blocked cell growth by inducing apoptosis (19). Similarly, JAK1 and JAK3 were found to be constitutively active in cells from patients suffering from adult T cell leukemia/lymphoma caused by human T cell leukemia/lymphotrophic virus type I (20). Furthermore, specific inhibition of JAKs inhibits the growth of multiple breast cancer cell lines and induces apoptosis in MDA-MB-468 breast cancer cells (21). The critical role of JAKs in so many normal physiological responses and their potential role in some cancers make it vitally important to obtain a better understanding of the mechanisms by which JAKs are regulated.

Recently, our laboratory identified the SH2 domain-containing protein SH2-Bbeta (22) as a potent activator of JAK2 (23). Addition of GH stimulates the phosphorylation of JAK2, leading to the association of SH2-Bbeta via its SH2 domain to one or more phosphorylated tyrosines in JAK2. This latter interaction substantially activates JAK2, thereby increasing the phosphorylation of JAK2 as well as of downstream targets of JAK2 such as Stat5B (23).

SH2-B is a member of a family of adapter proteins, which also includes APS and Lnk (24-26) (Fig. 1). All three contain a pleckstrin homology domain in their amino termini and an SH2 domain near their C termini. The various isoforms of SH2-B (alpha , beta , gamma , and delta ) also contain at least three proline-rich regions (22, 27, 28). Although we have shown SH2-Bbeta to be a positive regulator of JAK2 (23), studies by others suggest that APS and Lnk may be negative regulators of some signaling pathways. Lnk has been shown to play a pivotal role in the regulation of B cell production, as Lnk knockout mice show overproduction of pre-B cells in the spleen and pro-B cells in bone marrow (29). Overexpression of APS suppresses proliferation of NIH-3T3 cells as stimulated by platelet-derived growth factor (PDGF) (30). To date, the effects of APS and Lnk on the kinase activity and tyrosyl phosphorylation of JAKs have not been examined. Furthermore, SH2-Bbeta has not been examined as a regulator of JAKs other than JAK2. Because of the importance of the cytokine receptor family of ligands and the remarkable ability of SH2-Bbeta to activate JAK2, we examined whether the activating ability of SH2-Bbeta is specific to JAK2 or extends to other members of the JAK family of tyrosine kinases. We also examined whether the ability of SH2-Bbeta to activate JAK2 is shared by APS. Finally, we examined whether SH2-Bbeta or APS binds to JAK1, JAK2, or JAK3 and/or is tyrosyl-phosphorylated by any of these JAKs, thereby implicating SH2-Bbeta or APS as a signaling molecule for these JAKs.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1.   Schematic representation of members of the SH2-B family of putative adapter proteins. Potential sites of tyrosyl phosphorylation are shown (Y). P, proline-rich region; PH, pleckstrin homology domain; SH2, Src homology 2 domain. Schematics shown are for rat SH2-Bbeta , rat APS, and mouse Lnk. Numbers indicate amino acids. Percentages indicate similarity between domains.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Reagents-- The stocks of COS-7, 293T, and 3T3-F442A cells were provided by Drs. M. D. Uhler (University of Michigan, Ann Arbor, MI), O. A. MacDougald (University of Michigan), and H. Green (Harvard University, Cambridge, MA), respectively. Aprotinin, leupeptin, and Triton X-100 were from Roche Molecular Biochemicals. Recombinant protein A-agarose was from Repligen. The enhanced chemiluminescence detection system (ECL) was from Amersham Biosciences, Inc. Anti-JAK2 antiserum (alpha JAK2) was raised in rabbits against a synthetic peptide corresponding to amino acids 758-766 of murine JAK2 (31, 32) and was used at dilutions of 1:500 for immunoprecipitation and 1:15,000 for immunoblotting. Antibody against the Myc tag (alpha Myc; 9E10) was from Santa Cruz Biotechnology and was used for immunoblotting at a dilution of 1:10,000. For immunoprecipitation, alpha Myc was used at a dilution of 1:100 with rabbit anti-mouse IgG (1:100) (Upstate Biotechnology, Inc.). Monoclonal anti-phosphotyrosine antibody (alpha PY; clone 4G10; Upstate Biotechnology, Inc.) was used at a dilution of 1:7500 for immunoblotting. Antibody against murine JAK1 (alpha JAK1) was kindly provided by Dr. A. C. Larner (Learner Research Institute, Cleveland Clinic, Cleveland, OH) (33) and was used for immunoprecipitation at a dilution of 1:300. Polyclonal rabbit alpha JAK1 (Pharmingen) was used for immunoblotting at a dilution of 1:5000. alpha JAK3 was raised in rabbits against a synthetic peptide corresponding to amino acids 1104-1124 of human JAK3 (34) and was used at dilutions of 1:300 for immunoprecipitation and 1:3000 for immunoblotting. Anti-green fluorescent protein (GFP) antibody was from CLONTECH and was used at a dilution of 1:5000 for immunoblotting. Polyclonal rabbit anti-phospho-Stat5B antibody was from Zymed Laboratories Inc. and was used at a dilution of 1 µg/ml for immunoblotting. Anti-APS antibody (alpha APS) was kindly provided by Dr. D. D. Ginty (Johns Hopkins University School of Medicine, Baltimore, MD) (35) and was used at dilutions of 1:100 for immunoprecipitation and 1:1000 for immunoblotting.

Plasmids-- The cDNA for wild-type murine JAK2 was provided by Drs. J. N. Ihle and B. A. Witthuhn (St. Jude Children's Research Hospital, Memphis, TN) (31). The cDNA for human JAK3 was described previously (36, 37). The cDNA for murine JAK1 was provided by Drs. X. Yang and C. L. Cepko (Harvard Medical School, Boston MA) (38). cDNA encoding murine JAK1 with a Myc tag at its C terminus was kindly provided by Dr. R. D. Schreiber (Washington University, St. Louis, MO). Construction of the vector encoding SH2-Bbeta with a Myc tag at its N terminus has been described previously (23). cDNA encoding Myc-tagged rat APS was kindly provided by Dr. D. D. Ginty (35). cDNA encoding GFP-tagged Stat5B was constructed as described (39). cDNA encoding the rat GH receptor (GHR) was provided by Dr. G. Norstedt (Karolinska Institute, Stockholm, Sweden) (40).

Cell Culture and Transfection-- COS-7, 293T, and 3T3-F442A cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin (supplemented DMEM), and 10% fetal calf serum (COS-7 cells) or 8% calf serum (293T and 3T3-F442A cells). Cells were transiently transfected using calcium phosphate precipitation (41). Transfected cells were assayed 36-48 h after transfection. Before stimulating transfected cells with hormone, cells were incubated overnight in serum-free medium containing 1% bovine serum albumin and treated with ligands at 37 °C. 3T3-F442A fibroblasts were differentiated to adipocytes by treating confluent cells for 48 h with 2 µg/ml insulin, 0.25 µM dexamethasone, 0.5 mM methylisobutylxanthine, and 10% fetal calf serum in supplemented DMEM for 48 h. Cells were treated for an additional 48 h with supplemented DMEM containing 10% fetal calf serum and 1 µg/ml insulin (42). Adipocytes were maintained in supplemented DMEM plus 10% fetal calf serum. Before assays, cells were incubated overnight in serum-free medium containing 1% bovine serum albumin and treated with ligands at 37 °C.

Immunoprecipitation and Immunoblotting-- Immunoprecipitations and immunoblotting were performed as described (43). Thirty (293T cells) to 48 (COS-7 cells) h after transfection, cells were rinsed three times with 10 mM sodium phosphate (pH 7.4), 150 mM NaCl, and 1 mM Na3VO4. Cells were then solubilized in lysis buffer (50 mM Tris (pH 7.5), 0.1% Triton X-100, 150 mM NaCl, 2 mM EGTA, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, and 10 µg/ml leupeptin) and centrifuged at 14,000 × g for 10 min at 4 °C. The supernatant (cell lysate) was incubated with the indicated antibody on ice for 2 h. The immune complexes were collected on protein A-agarose (14-µl packed volume) for 1 h at 4 °C. The beads were washed three times with wash buffer (50 mM Tris (pH 7.5), 0.1% Triton X-100, 150 mM NaCl, and 2 mM EGTA) and boiled for 5 min in a 80:20 mixture of lysis buffer and SDS-PAGE sample buffer (250 mM Tris-HCl (pH 6.8), 10% SDS, 10% beta -mercaptoethanol, 40% glycerol, and 0.01% bromphenol blue). The solubilized proteins were separated by SDS-PAGE (7.5 or 5-12% gradient), followed by immunoblotting with the indicated antibody and visualization with the ECL detection system.

In Vitro Kinase Assay-- In vitro kinase assays were performed as described previously (43). JAKs were immunoprecipitated with the appropriate alpha JAK using protein A-agarose. Bound proteins were washed twice with lysis buffer and twice with kinase buffer (50 mM HEPES (pH 7.6), 5 mM MnCl2, 0.5 mM dithiothreitol, 100 mM NaCl, and 1 mM Na3VO4). Immunoprecipitates were incubated at 30 °C for 30 min in 50 µl of kinase buffer containing [gamma -32P]ATP, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. Immunoprecipitates were washed once with 500 µl of kinase buffer supplemented with 10 mM EDTA, followed by three washes with 500 µl of lysis buffer. Proteins were eluted by boiling in a 4:1 mixture of lysis buffer and SDS-PAGE sample buffer. Proteins were then resolved by SDS-PAGE (7.5 or 5-12% gradient), transferred to nitrocellulose membrane, and visualized by autoradiography, followed by immunoblotting with the appropriate alpha JAK.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Differential Ability of SH2-Bbeta to Activate JAK1, JAK2, and JAK3-- We have shown previously that SH2-Bbeta is a potent activator of JAK2 (23). To determine whether the activation of JAK2 by SH2-Bbeta is specific to JAK2 or shared by other members of the Janus family of tyrosine kinases, we examined whether SH2-Bbeta could also activate JAK1. Like JAK2, JAK1 is widely expressed and is activated by an overlapping set of ligands, including GH, leukemia inhibitory factor, and granulocyte colony-stimulating factor (2). We also examined whether SH2-Bbeta could activate JAK3, which is activated by ligands that are not potent activators of JAK2 such as IL-7 (3). Initially, we assessed the kinase activity of JAK3 using an in vitro kinase assay. For comparison, the experiment was performed concurrently with JAK2. cDNA encoding the appropriate JAK was transfected alone or with cDNA encoding Myc-tagged SH2-Bbeta in COS-7 cells. The expressed JAK was immunoprecipitated with the appropriate alpha JAK and incubated with [gamma -32P]ATP. The immunoprecipitated proteins were separated by SDS-PAGE and transferred to nitrocellulose. 32P-Labeled proteins were visualized by autoradiography, and the amount of immunoprecipitated JAK was determined by immunoblotting with the appropriate alpha JAK. As reported previously (23), JAK2 was constitutively active when overexpressed in COS-7 cells (Fig. 2A, lane 1, upper panel). Furthermore, its in vitro kinase activity was substantially increased by the coexpression of SH2-Bbeta (lane 2, upper panel). JAK3 was also constitutively active when overexpressed in COS-7 cells (lane 3, upper panel). However, in contrast to JAK2, JAK3 was not activated by coexpression with SH2-Bbeta (lane 4, upper panel). Similar results were obtained when JAK2 and JAK3 were expressed in 293T cells (data not shown).


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 2.   SH2-Bbeta stimulates the kinase activity and tyrosyl phosphorylation of JAK2, but not of JAK1 or JAK3. Plasmid (5 µg) encoding Myc alone (lanes 1 and 3) or Myc-SH2-Bbeta (lanes 2 and 4) was cotransfected with plasmid encoding either JAK2 (2 µg) or JAK3 (2 µg) into COS-7 cells (A) or JAK2 (0.5 µg) or Myc-JAK1 (5 µg) into 293T cells (B) as indicated. Cell lysates were immunoblotted with alpha Myc (lower panels). Proteins from cell lysates were also immunoprecipitated (IP) with the indicated alpha JAK. A, immunoprecipitated JAKs were subjected to an in vitro kinase assay with 25 µCi of [gamma -32P]ATP and resolved by SDS-PAGE. Proteins were visualized by autoradiography (32P) (upper panels) and then immunoblotted (IB) with the indicated alpha JAK (middle panels). B, immunoprecipitated JAKs were immunoblotted with the indicated alpha JAK (middle panels) and reprobed with alpha PY (upper panels).

We next examined the ability of SH2-Bbeta to increase the in vitro kinase activity of JAK1. cDNA encoding JAK1 (or JAK2 for comparison) was transfected into 293T cells alone or with cDNA encoding Myc-tagged SH2-Bbeta . 293T cells were used to overexpress JAK1 because we had difficulty overexpressing JAK1 in COS-7 cells. Kinase assays with JAK1 were performed with [gamma -32P]ATP as described for JAK3. However, JAK1 incorporated only a small amount of [gamma -32P]ATP in vitro compared with JAK2 and JAK3, raising the possibility that our anti-JAK1 antibodies interfere with the in vitro kinase assay. We therefore probed JAK1 (and JAK2) with alpha PY to examine the effects of overexpressed SH2-Bbeta on the tyrosyl phosphorylation of JAK1 (and JAK2). The tyrosyl phosphorylation of JAKs is thought to reflect their autophosphorylation. SH2-Bbeta increased the tyrosyl phosphorylation of JAK2 (Fig. 2B, lane 2, upper panel) consistent with increased activity of JAK2. However, SH2-Bbeta had no reproducible effect on the tyrosyl phosphorylation of JAK1 (lane 4, upper panel), suggesting that SH2-Bbeta has no effect on the activity of JAK1.

JAK1, but Not JAK3, Phosphorylates SH2-Bbeta -- SH2-Bbeta binds to JAK2 (Fig. 3A) as assessed by coprecipitation experiments using overexpressed or endogenous JAK2 and SH2-Bbeta (22). Furthermore, we have shown that overexpressed JAK2 tyrosyl-phosphorylates overexpressed SH2-Bbeta both in vivo and in vitro and that endogenous SH2-Bbeta is phosphorylated on tyrosines in 3T3-F442A cells in response to GH and IFN-gamma , two ligands that activate JAK2 (22). This tyrosyl phosphorylation suggests that SH2-Bbeta may also function as an adapter protein for ligands that activate JAK2 by recruiting proteins that bind phosphotyrosines to JAK2·SH2-Bbeta complexes. To determine whether SH2-Bbeta might also serve as a signaling protein for ligands that activate JAK1 and JAK3, even though SH2-Bbeta does not appear to activate these JAKs, we examined whether either JAK1 or JAK3 associates with and/or phosphorylates SH2-Bbeta . Myc-tagged SH2-Bbeta was transiently overexpressed with JAK1 or JAK2 in 293T cells or with JAK3 in COS-7 cells. Myc-SH2-Bbeta was immunoprecipitated with alpha Myc, and precipitated proteins were blotted with the appropriate alpha JAK. As reported previously (22), SH2-Bbeta coprecipitated with JAK2 (Fig. 3A, lane 2, upper panel). It also coprecipitated with JAK1 (Fig. 3B, lane 2, upper panel)2 and JAK3 (Fig. 3C, lane 2, upper panel), suggesting that SH2-Bbeta forms a complex with all three of these JAKs. To determine whether SH2-Bbeta is tyrosyl-phosphorylated when overexpressed with JAK1, JAK2, or JAK3, the blots were reprobed with alpha PY. As shown in Fig. 3A (lane 4), SH2-Bbeta was strongly phosphorylated on tyrosines when coexpressed with JAK2. Interestingly, although SH2-Bbeta did not seem to stimulate JAK1, SH2-Bbeta was phosphorylated on tyrosines in cells overexpressing JAK1 (Fig. 3B, lane 4). No phosphorylation of SH2-Bbeta was detected when cells were transfected with SH2-Bbeta alone (data not shown), as reported previously (22), consistent with SH2-Bbeta being phosphorylated on tyrosines by JAK1. In contrast, no tyrosyl phosphorylation of SH2-Bbeta was detected in cells overexpressing JAK3 (Fig. 3C, lane 4). Thus, the ability of SH2-Bbeta to activate appears to be specific to JAK2. However, SH2-Bbeta appears to bind to both JAK1 and JAK3 and to serve as a substrate of JAK1. These data suggest that SH2-Bbeta may serve as an adapter protein for ligands that activate JAK1 as well as for ligands that activate JAK2 via binding of signaling molecules to phosphorylated tyrosines in SH2-Bbeta and possibly to other binding motifs within SH2-Bbeta . Although signaling proteins that bind preferentially to phosphorylated tyrosines would not be expected to be recruited to SH2-Bbeta complexed to JAK3, SH2-Bbeta may still serve as a signaling molecule for ligands that activate JAK3 by recruiting molecules that bind other motifs (e.g. pleckstrin homology and proline-rich regions) within SH2-Bbeta to JAK3·SH2-Bbeta complexes.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 3.   JAK1 and JAK2, but not JAK3, phosphorylate SH2-Bbeta . Plasmid (5 µg) encoding Myc alone (lanes 1, 3, and 5) or Myc-SH2-Bbeta (lanes 2, 4, and 6) was cotransfected with plasmid encoding JAK2 (7 µg; 293T cells) (A), JAK1 (16 µg; 293T cells) (B), or JAK3 (5 µg; COS-7 cells) (C) as indicated. Proteins from cell lysates were immunoprecipitated (IP) with alpha Myc. Proteins were resolved by SDS-PAGE and immunoblotted (IB) with the indicated alpha JAK (lanes 1 and 2, upper panels). Proteins were reprobed with alpha PY (lanes 3 and 4) and then stripped and reprobed with alpha Myc (lanes 1 and 2, lower panels). Cell lysates were also immunoblotted directly with alpha JAK (lanes 5 and 6).

APS Increases the Phosphorylation of Overexpressed JAK2-- Because SH2-Bbeta activates some but not all JAKs and is tyrosyl-phosphorylated by some but not all JAKs, we hypothesized that other members of the SH2-B family might also activate, bind to, or serve as substrates of specific JAKs. To test this hypothesis, we first examined whether APS increases the kinase activity of JAK2. JAK2 cDNA was cotransfected with cDNA encoding Myc-tagged APS or Myc-tagged SH2-Bbeta into 293T cells. JAK2 was immunoprecipitated and incubated with [gamma -32P]ATP in an in vitro kinase assay. Like SH2-Bbeta , APS increased JAK2 activity (Fig. 4A, upper panel, lane 2 versus lane 3). We also examined whether APS increases the tyrosyl phosphorylation of JAK2 in vivo. Increasing amounts of JAK2 cDNA (0.25-2.0 µg) were transfected with cDNA encoding Myc-SH2-Bbeta or Myc-APS in 293T cells. Proteins in whole cell lysates were separated by SDS-PAGE and immunoblotted with alpha JAK2 (Fig. 4B, lower panels) and reprobed with alpha PY (upper panels). SH2-Bbeta substantially increased the phosphorylation of JAK2 at both low and high levels of JAK2 expression, with the highest percentage increase being observed in cells expressing the lowest level of JAK2 (0.25 µg) (Fig. 4B, lane 3). Consistent with the in vitro data shown in Fig. 4A, APS increased the tyrosyl phosphorylation of JAK2 when 2 µg of JAK2 cDNA were transfected (Fig. 4B, lane 9). When 0.5 or 1 µg of JAK2 was used, APS modestly increased JAK2 phosphorylation (lanes 5 and 7). In contrast to SH2-Bbeta , APS had no detectable effect on JAK2 phosphorylation in cells transfected with 0.25 µg of JAK2 cDNA (lane 2).


View larger version (41K):
[in this window]
[in a new window]
  		Fig. 4.   APS stimulates the kinase activity of JAK2 at high but not low levels of JAK2. A, plasmid (5 µg) encoding Myc alone (lane 1), Myc-SH2-Bbeta (lane 2), or Myc-APS (lane 3) was cotransfected with plasmid encoding JAK2 (2 µg) into 293T cells. Proteins from cell lysates were immunoprecipitated (IP) with alpha JAK2. Immunoprecipitated JAK2 was subjected to an in vitro kinase assay with 12.5 µCi of [gamma -32P]ATP and resolved by SDS-PAGE. Proteins were visualized by autoradiography (32P) (upper panel) and then by immunoblotting (IB) with alpha JAK2 (middle panel). Cell lysates were immunoblotted directly with alpha Myc (lower panel). B, plasmid (5 µg) encoding Myc alone (lanes 1, 4, 6, and 8), Myc-SH2-Bbeta (lanes 3 and 10), or Myc-APS (lanes 2, 5, 7, and 9) was cotransfected with plasmid encoding JAK2 (as indicated) into 293T cells. Proteins from whole cell lysates were resolved by SDS-PAGE and visualized by immunoblotting with alpha PY (upper panels) or alpha JAK2 (lower panels).

APS Decreases GH-stimulated Tyrosyl Phosphorylation of JAK2-- Because APS appeared to increase JAK2 phosphorylation in vivo at the higher levels of overexpressed JAK2, but not at the lowest level, we examined whether APS increases the phosphorylation of endogenous GH-stimulated JAK2. cDNA encoding rat GHR was cotransfected with cDNA encoding Myc-tagged SH2-Bbeta or Myc-tagged APS in 293T cells. 24 h after transfection, cells were deprived of serum overnight and stimulated with 50 or 500 ng/ml human GH for 10 min. Protein concentrations were measured in whole cell lysates, and endogenous JAK2 was immunoprecipitated from lysates containing equal amounts of protein. Proteins in the immunoprecipitates were separated by SDS-PAGE and immunoblotted with alpha PY. As reported previously (23), SH2-Bbeta increased GH-stimulated tyrosyl phosphorylation of endogenous JAK2 (Fig. 5A, lane 1 versus lane 3). SH2-Bbeta was unable to stimulate further the tyrosyl phosphorylation of endogenous JAK2 when a maximally stimulating dose of human GH (500 ng/ml) was used. In contrast to SH2-Bbeta , APS failed to increase the tyrosyl phosphorylation of endogenous JAK2 at either the submaximal (50 ng/ml) or maximal (500 ng/ml) dose of human GH (lanes 2 and 5). In the experiment shown, APS appeared to block GH stimulation of endogenous JAK2. In other experiments, the inhibition by APS was less pronounced, but present nonetheless. Overexpression of neither SH2-Bbeta nor APS consistently altered the amount of endogenous JAK2 detected in alpha JAK2 blots of JAK2 immunoprecipitates (data not shown). Interestingly, endogenous JAK2 often appears as a doublet in the presence or absence of overexpressed SH2-Bbeta . In the presence of SH2-Bbeta , the upper, slower migrating band is usually darker than the lower, faster migrating band. This slower migrating band presumably represents a more highly phosphorylated form of JAK2. In contrast, endogenous JAK2 consistently appears as a single, lower band in the presence of overexpressed APS. These results indicate that SH2-Bbeta enhances the tyrosyl phosphorylation (and perhaps serine/threonine phosphorylation) of JAK2, whereas APS, if anything, blocks or inhibits the phosphorylation of JAK2.


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 5.   APS decreases GH-stimulated JAK2 activity. A, plasmid (5 µg) encoding GHR was transfected into 293T cells with plasmid (5 µg) encoding Myc alone (lanes 1 and 4), Myc-APS (lanes 2 and 5), or Myc-SH2-Bbeta (lanes 3 and 6). Cells were stimulated with GH as indicated for 10 min. Equal amounts of protein were immunoprecipitated (IP) with alpha JAK2 and resolved by SDS-PAGE. Proteins were visualized by immunoblotting (IB) with alpha PY. B, plasmids (5 µg) encoding GHR and GFP-Stat5B were transfected into 293T cells with plasmid (5 µg) encoding Myc alone (lanes 1, 4, and 7), Myc-SH2-Bbeta (lanes 2, 5, and 8), or Myc-APS (lanes 3, 6, and 9). Cells were stimulated with GH as indicated for 10 min. Proteins from cell lysates were resolved by SDS-PAGE and immunoblotted with anti-phospho-Stat5B antibody (alpha pSTAT5B; upper panel) and reprobed with anti-GFP antibody (alpha GFP; lower panel).

To provide evidence that APS decreases signaling by ligands that activate JAK2, we examined the effect of APS on GH-dependent tyrosyl phosphorylation of the JAK2 substrate Stat5B. 293T cells were cotransfected with cDNA encoding GHR and GFP-Stat5B and either Myc-SH2-Bbeta or Myc-APS. Twenty-four h after transfection, cells were deprived of serum overnight and stimulated with 50 or 500 ng/ml human GH for 10 min. Proteins from whole cell lysates were separated by SDS-PAGE and Western-blotted with antibody recognizing phosphorylated tyrosine 694 in Stat5B. This is the tyrosine whose phosphorylation by JAKs is necessary for activation of Stat5 (44). SH2-Bbeta increased GH-dependent tyrosyl phosphorylation of Stat5B at 50 ng/ml GH, but not at 500 ng/ml GH, as predicted from the JAK2 experiment above (Fig. 5B, lanes 5 and 8). In contrast, APS substantially decreased GH-stimulated phosphorylation of Stat5B at both low and high doses of GH (lanes 6 and 9).

APS Inhibits JAK1, but Not JAK3-- We next investigated whether APS has any effect on the kinase activity or tyrosyl phosphorylation of JAK1 or JAK3. We first examined the effects of APS on JAK1. As described above, JAK1 had little in vitro kinase activity; therefore, we examined the tyrosyl phosphorylation of JAK1 by immunoblotting with alpha PY. Myc-tagged APS (or Myc-tagged SH2-Bbeta for comparison) was expressed with increasing amounts of JAK1 in 293T cells. JAK1 was immunoprecipitated and immunoblotted with alpha JAK1 followed by alpha PY. As shown in Fig. 2B, coexpression of SH2-Bbeta had no effect on the tyrosyl phosphorylation of JAK1 (Fig. 6A, lanes 2, 5, and 8). In contrast, coexpression of APS caused a decrease in the tyrosyl phosphorylation of JAK1 without a corresponding decrease in JAK1 protein (lanes 3, 6, and 9). In two of seven experiments, the APS-induced decrease in the tyrosyl phosphorylation of JAK1 was accompanied by a small decrease in the amount of JAK1 protein (data not shown). However, the observed decrease in the tyrosyl phosphorylation of JAK1 was substantially greater than the decrease in the amount of JAK1.


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 6.   APS decreases the phosphorylation of JAK1, but not of JAK3. A, plasmid encoding Myc-JAK1 was transfected into 293T cells with plasmid (5 µg) encoding Myc alone (lanes 1, 4, and 7), Myc-SH2-Bbeta (lanes 2, 5, and 8), or Myc-APS (lanes 3, 6, and 9). Proteins from cell lysates were immunoprecipitated (IP) with alpha JAK1 and resolved by SDS-PAGE. Proteins were immunoblotted (IB) with either alpha PY (upper panel) or alpha JAK1 (lower panel). B, plasmid (2 µg) encoding JAK3 was transfected into COS-7 cells with plasmid (5 µg) encoding Myc alone (lane 1), Myc-SH2-Bbeta (lane 2), or Myc-APS (lane 3). Proteins from cell lysates were immunoprecipitated with alpha JAK3 and subjected to in vitro kinase assay with 25 µCi of [gamma -32P]ATP. Proteins were resolved by SDS-PAGE and visualized by autoradiography (32P) (upper panels) and then immunoblotted with alpha JAK3 (middle panels). Proteins from whole cell lysates were immunoblotted with alpha Myc (lower panels).

We next examined the effects of APS on the activity JAK3. JAK3 was expressed with Myc-SH2-Bbeta or Myc-APS in COS-7 cells. JAK3 was immunoprecipitated and incubated with [gamma -32P]ATP as described above. As shown in Fig. 2B, SH2-Bbeta had no effect on JAK3 activity when slight differences in the levels of JAK3 are taken into account (Fig. 6B, lane 2). Like SH2-Bbeta , APS had no reproducible effect on the activity of JAK3 (lane 3).

JAK1 and JAK3 Phosphorylate APS-- To determine whether APS binds to and/or is a substrate of any of the JAKs, JAK1, JAK2, or JAK3 was overexpressed with Myc-APS (or Myc-SH2-Bbeta for comparison). Myc-SH2-Bbeta and Myc-APS were immunoprecipitated using alpha Myc, and the immunoprecipitated proteins were immunoblotted first with alpha PY to detect phosphorylated proteins. The blots were also probed with the appropriate alpha JAK to detect association of JAK1, JAK2, or JAK3 with APS and then stripped and reprobed with alpha Myc to compare the levels of expression of Myc-APS and Myc-SH2-Bbeta . Additionally, cell lysates were immunoblotted with the appropriate alpha JAK to verify equal expression of JAK in the APS- and SH2-Bbeta -overexpressing cells. As shown in Fig. 3, SH2-Bbeta was tyrosyl-phosphorylated when expressed with JAK1 (Fig. 7B, lane 5) and JAK2 (Fig. 7A, lane 5), but not with JAK3 (Fig. 7C, lane 5). In contrast to what was observed with SH2-Bbeta , all three JAKs stimulated the tyrosyl phosphorylation of APS (Fig. 7, A-C, lane 6). SH2-Bbeta and APS appeared to bind similar amounts of JAK1 (Fig. 7B, lane 3, upper panel) and JAK2 (Fig. 7A, lane 3, upper panel). However, APS appeared to bind more JAK3 than was bound by SH2-Bbeta (Fig. 7C, lane 3, upper panel). Interestingly, the JAK1 that bound to APS appeared to not be phosphorylated on tyrosines (Fig. 7B, lane 6). Taken together, Figs. 5-7 indicate that APS binds to all three JAKs and that all three JAKs are able to phosphorylate APS. Furthermore, APS is a weak activator of overexpressed JAK2 in vitro and an inhibitor of GH-stimulated JAK2 and of overexpressed JAK1 in vivo.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 7.   JAK1, JAK2, and JAK3 phosphorylate APS. Plasmid (5 µg) encoding Myc alone (lanes 1, 4, and 7), Myc-SH2-Bbeta (lanes 2, 5, and 8), or Myc-APS (lanes 3, 6, and 9) was cotransfected with plasmid encoding JAK2 (7 µg; COS-7 cells) (A), JAK1 (16 µg; 293T cells) (B), or JAK3 (5 µg; COS-7 cells) (C). Proteins from cell lysates were immunoprecipitated (IP) with alpha Myc, resolved by SDS-PAGE, and immunoblotted (IB) with the indicated alpha JAK (lanes 1-3, upper panels). Proteins were reprobed with alpha PY (lanes 4-6) followed by alpha Myc (lanes 1-3, lower panels). Cell lysates were immunoblotted directly with alpha JAK (lanes 7-9). For comparison purposes, lanes 1 and 2, 4 and 5, and 8 and 9 in B show the results of lanes 1 and 2, 3 and 4, and 5 and 6 in Fig. 4B, in which JAK1 was coexpressed with Myc alone or with Myc-SH2-Bbeta .

APS Is Tyrosyl-phosphorylated in Response to GH in Adipocytes-- To verify that endogenous APS is tyrosyl-phosphorylated in response to cytokines and growth factors that activate JAKs, consistent with APS being a substrate of JAKs, 3T3-F442A adipocytes were deprived of serum overnight and then stimulated for 10 min with human GH (500 ng/ml), murine IFN-gamma (10 ng/ml), or human insulin (100 nM) as a positive control. APS was immunoprecipitated and Western-blotted with alpha PY. We observed that APS was tyrosyl-phosphorylated in response to insulin (Fig. 8A, lane 4, upper panel), as reported previously (45, 46). GH also stimulated the tyrosyl phosphorylation of APS (lane 2, upper panel), as predicted from the ability of JAK2 to tyrosyl-phosphorylate APS. IFN-gamma weakly stimulated the phosphorylation of APS (lane 3, upper panel), consistent with the significantly decreased ability of IFN-gamma to activate JAK2 compared with GH in these cells (47).


View larger version (54K):
[in this window]
[in a new window]
  		Fig. 8.   APS is tyrosyl-phosphorylated in response to GH. A, 3T3-F442A adipocytes were treated for 15 min with 500 ng/ml GH (lane 2), 25 ng/ml IFN-gamma (lane 3), or 100 nM insulin (lane 4). Proteins from cell lysates were immunoprecipitated (IP) with alpha APS. Proteins were resolved by SDS-PAGE and immunoblotted with alpha PY (upper panels) and then reprobed with alpha APS (lower panels). B, 3T3-F442A adipocytes were treated with 25 ng/ml GH for the indicated times. Proteins from cell lysates were immunoprecipitated with alpha APS (upper panel) or anti-SH2-Bbeta antibody (alpha SH2-Bbeta ) (lower panel). Proteins were resolved by SDS-PAGE and immunoblotted with alpha PY.

To determine whether APS and SH2-Bbeta are tyrosyl-phosphorylated within the same time period in cells expressing both proteins, 3T3-F442A adipocytes were deprived of serum overnight and stimulated with 25 ng/ml GH for 1, 5, 15, 30, or 60 min. APS (Fig. 8B, upper panel) or SH2-Bbeta (lower panel) was immunoprecipitated and Western-blotted with alpha PY. The tyrosyl phosphorylation of both APS and SH2-Bbeta was detectable within 5 min of GH stimulation (lane 3), maximal at 30 min (lane 5), and decreased by 60 min after GH treatment (lane 6).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

SH2-Bbeta Is a Specific Activator of JAK2-- We have demonstrated previously that SH2-Bbeta is a potent activator of JAK2 (23). In the present study, we have shown that SH2-Bbeta fails to activate JAK1 or JAK3. This conclusion is based on results from in vitro kinase assays and/or detection of tyrosyl-phosphorylated JAK by Western blotting with alpha PY. The simplest explanation for why SH2-Bbeta activates JAK2, but not JAK1 or JAK3, would be if JAK2 contains a binding site for SH2-Bbeta , whereas JAK1 and JAK3 do not. However, both JAK1 and JAK3 coprecipitated with SH2-Bbeta (Fig. 3), indicating that both JAK1 and JAK3 can bind SH2-Bbeta . Previous studies revealed two sites of interaction between JAK2 and SH2-Bbeta , only one of which is required for activation of JAK2 (43). The interaction site required for SH2-Bbeta activation of JAK2 involves the SH2 domain of SH2-Bbeta and phosphorylated tyrosines within JAK2. In contrast, the second site of interaction between SH2-Bbeta and JAK2 lies within the first 555 amino acids of SH2-Bbeta , a region that does not include an intact SH2 domain. Based on this model, one could hypothesize that JAK2 contains both binding sites for SH2-Bbeta , whereas JAK1 and JAK3 contain only the non-activating site. However, SH2-Bbeta binds better to wild-type JAK3 than to kinase-inactive JAK3 (data not shown), suggesting that SH2-Bbeta binds to (presumably via its SH2 domain) phosphorylated tyrosines within JAK3. This suggests that binding of SH2-Bbeta to phosphorylated tyrosines within JAK molecules is not sufficient to activate JAKs.

One can envision several alternative scenarios by which JAK2 is activated by binding to SH2-Bbeta , but JAK1 and JAK3 are not. For example, SH2-Bbeta binding to a specific phosphorylated tyrosine within JAK2 may cause a conformational change that exposes the ATP- or substrate-binding site. The sites that SH2-Bbeta binds to in JAK1 and JAK3 may not cause the same conformational change, perhaps because the sites are located on different regions of the JAK molecules. Another possibility is that SH2-Bbeta binding relieves inhibition of the kinase activity of JAK2 by another region in JAK2 such as the kinase-like JH2 domain (48). Again, SH2-Bbeta could be binding to tyrosines located outside the JH1 or JH2 domains on JAK1 and JAK3 with the result that SH2-Bbeta binding does not relieve the inhibition. SH2-Bbeta could also be competing for binding to JAK2 with an inhibitor of JAK2 such as a member of the SOCS family or a tyrosine phosphatase. The SH2-Bbeta -binding site within JAK1 and JAK3 may be sufficiently different from the JAK2 counterpart such that SH2-Bbeta fails to compete with the pertinent inhibitor. Finally, dimerization has been hypothesized to be required for JAK activation (49). SH2-Bbeta may enhance the dimerization of JAK2, but not of JAK1 or JAK3. A role for dimerization in the activation of TrkA kinase activity by SH2-B has been hypothesized by Qian and Ginty (50).

SH2-Bbeta Is Phosphorylated by JAK1 and JAK2, but Not by JAK3-- SH2-Bbeta contains multiple potential protein-protein interaction domains and is differentially phosphorylated on tyrosines and/or serines/threonines in response to a variety of ligands, including GH, nerve growth factor, PDGF, brain-derived neurotrophic factor, and epidermal growth factor (22, 24, 35, 51-54). These observations suggest that SH2-Bbeta may play a role as an adapter protein in cell signaling in addition to its role as an activator of JAK2. An adapter role for SH2-Bbeta is supported by the observation that SH2-Bbeta binds JAK1 and is tyrosyl-phosphorylated by JAK1, but fails to increase the tyrosyl phosphorylation of JAK1. SH2-Bbeta may act as an adapter protein for cytokines that activate JAK1 by recruiting proteins containing SH2 or phosphotyrosine-binding domains into receptor·JAK·SH2-Bbeta complexes. It is interesting to note that SH2-Bbeta is not phosphorylated on tyrosines when coexpressed with JAK3. Thus, even though JAK3 can bind SH2-Bbeta , JAK3 does not phosphorylate SH2-Bbeta on tyrosines, even under conditions in which the kinase activity of JAK3 is very high. This finding is consistent with reports that the substrate specificities of JAK1 and JAK2 are similar to each other, but differ from that of JAK3 (55).

APS Decreases the Tyrosyl Phosphorylation of JAK1 and JAK2-- The finding that SH2-Bbeta is a potent activator of JAK2, but not of JAK1 or JAK3, led us at one time to hypothesize that APS might activate a different subset of JAKs than SH2-Bbeta . The data presented here argue against this hypothesis. In fact, they argue for APS having, under the appropriate conditions, the opposite effect of SH2-Bbeta , i.e. inhibiting JAK2. In support of this, APS decreased GH-dependent phosphorylation of JAK2 and a substrate of JAK2, Stat5B. The ability of APS to decrease phospho-JAK2 (and presumably JAK2 activity) may decrease the transcriptional activity of Stat5B because the tyrosyl phosphorylation of Stat5B by JAK2 is required for activation of Stat5B. Stat5B initiates transcription of a variety of genes in response to GH, including spi2.1, insulin-1, cytochrome P450 beta -hydroxylase (CYP3A), and the acid labile subunit (56-61). Stat5B is also implicated in the GH-dependent expression of insulin-like growth factor-1 (62, 63). Consistent with the decreased phosphorylation of Stat5B demonstrated here, Wakioka et al. (64) showed that overexpression of APS decreases erythropoietin (EPO)-dependent phosphorylation of Stat5B with a concurrent decrease in transcriptional activity. Our data add to this observation by suggesting that the mechanism of the decreased Stat5B phosphorylation is at least in part due to a decrease in JAK2 phosphorylation. Furthermore, it is reasonable to hypothesize that other signaling pathways downstream of JAK2 would also be decreased. Other demonstrated targets of JAK2 include insulin receptor substrates (15, 16); focal adhesion kinase (17); and Shc, an adapter protein that lies upstream of the MAPKs ERK1 and ERK2 (14). For this inhibitory effect, APS appears to be acting at the level of JAK2 rather than GHR because our preliminary experiments suggest that APS fails to decrease GHR protein levels or the ability of GHR to bind GH (data not shown). Interestingly, however, APS modestly stimulates JAK2 when both are overexpressed in 293T cells. But in contrast to SH2-Bbeta , which becomes more efficient at stimulating JAK2 with decreasing amounts of JAK2, APS became less efficient (in terms of -fold stimulation).

The findings that overexpressed APS decreases phosphorylation of endogenous JAK2 but activates overexpressed JAK2 and increases its tyrosyl phosphorylation suggest that APS has two conflicting functions: one results in the inhibition of JAK2, and the other is to activate JAK2. It seems likely that inhibition is the more physiologically relevant function because it prevails at endogenous levels of JAK2. These conflicting functions could be explained if the inhibitory function requires another, endogenous protein that is present in sufficient quantities in 293T cells to inhibit endogenous levels of JAK2, but is not in sufficient quantities to inhibit overexpressed levels of JAK2. One candidate for this protein is c-Cbl. c-Cbl has been shown to bind APS in response to stimulation by PDGF, EPO, and insulin (30, 64, 65). It has also been shown to cause the ubiquitination and degradation of the receptors for PDGF, epidermal growth factor, and insulin as well as several non-receptor tyrosine kinases, including Syk and Fyn (66). The association between APS and c-Cbl has been hypothesized to lead to the ubiquitination and subsequent degradation of the insulin receptor (65), inhibition of PDGF-stimulated c-fos promoter activation, and reduced activation of Stat5B in response to EPO (64). If c-Cbl is acting with APS to lead to the ubiquitination of tyrosyl-phosphorylated JAK2, we would expect to see an APS-induced decrease in the amount of endogenous JAK2. Although we did not see an overall decrease in JAK2, we did observe that the more highly tyrosyl-phosphorylated form of JAK2 that migrates slower than unphosphorylated JAK2 is not detected in cells overexpressing APS. This raises the possibility that APS promotes the degradation of the most highly phosphorylated form of JAK2, which, under our assay conditions, usually represents only a small portion of total JAK2 protein. However, our preliminary experiments have not implicated c-Cbl in the APS-dependent decrease in the tyrosyl phosphorylation of JAK2. Coexpression of JAK2 with c-Cbl increased the tyrosyl phosphorylation of JAK2 in both the presence and absence of overexpressed APS (data not shown). Further studies are required to determine whether Cbl family members associate with APS/JAK2 in response to GH and stimulate ubiquitination of JAK2 or whether other, as yet unidentified proteins are involved in the negative regulation of JAKs by APS.

Consistent with the ability of overexpressed APS to decrease the tyrosyl phosphorylation of endogenous JAK2, overexpression of APS decreased the tyrosyl phosphorylation of JAK1. As hypothesized for JAK2, APS may promote the degradation of tyrosyl-phosphorylated JAK1. This hypothesis is supported by the fact that only unphosphorylated JAK1 coprecipitated with APS, although JAK1 tyrosyl-phosphorylated APS. In contrast to the negative effects of APS on the tyrosyl phosphorylation of JAK1 and JAK2, APS had no effect on JAK3 kinase activity or tyrosyl phosphorylation, indicating that the regulation of JAK3 by SH2-B family members differs from that of JAK1 and JAK2.

APS Is Phosphorylated in Response to Cytokines and Growth Factors That Activate JAKs-- APS was found to be tyrosyl-phosphorylated when coexpressed with JAK1 or JAK2. Furthermore, in contrast to SH2-Bbeta , APS was phosphorylated when coexpressed with JAK3. These findings indicate that APS is likely to function as an adapter protein for cytokines and growth factors that activate JAK1, JAK2, and JAK3. Consistent with this hypothesis, we have demonstrated that in 3T3-F442A adipocytes, endogenous APS is tyrosyl-phosphorylated in response to GH, a potent activator of JAK2 and a weak activator of JAK1 (47). The phosphorylation of APS appears to parallel that of SH2-Bbeta in that both proteins are tyrosyl-phosphorylated within 5 min of GH stimulation, and their phosphorylation decreases by 60 min after GH treatment (Fig. 8B). Furthermore, our data indicate that GH is a more potent stimulator of APS phosphorylation than insulin in these cells. Our data also indicate that APS is weakly phosphorylated in response to IFN-gamma (Fig. 8A) and leukemia inhibitory factor (data not shown), cytokines that are weak activators of JAK1 and JAK2 in these cells (47). These experiments using endogenous APS are consistent with the findings of Wakioka et al. (64) that overexpressed APS is tyrosyl-phosphorylated in response to stimulation by IFN-gamma , EPO, and leukemia inhibitory factor and that highly expressed APS is tyrosyl-phosphorylated in response to IFN-gamma in the osteosarcoma cell line Saos-2. The data are also consistent with the finding by Iseki et al. (67) that IL-3 and IL-5, potent activators of JAK2, stimulate the tyrosyl phosphorylation of overexpressed APS.

What are the implications of our results for the physiological functions of SH2-Bbeta and APS? First, our data suggest that SH2-Bbeta provides a powerful positive feedback mechanism for ligands that stimulate JAK2. Because SH2-Bbeta fails to activate JAK1 or JAK3, SH2-Bbeta would increase signals stimulated by ligands that activate JAK2, but not JAK1 or JAK3. This difference may provide one explanation for why GH is a much more powerful activator of JAK2 than of JAK1 in 3T3-F442A cells. 3T3-F442A cells contain a substantial amount of SH2-Bbeta . Second, SH2-Bbeta may serve as an adapter for JAK1 and JAK2, but not for JAK3, by providing phosphorylated tyrosine(s) that can recruit other signaling proteins to receptor·JAK·SH2-Bbeta complexes. Third, in contrast to SH2-Bbeta , APS may provide an equally powerful negative feedback mechanism for ligands that activate JAK1 and/or JAK2. This role may overlap with the ability of APS to function as an adapter protein in that ligand stimulation would cause the association of APS and JAKs and the subsequent phosphorylation of APS. Phosphotyrosines on APS may provide binding sites for downstream molecules that decrease the phosphorylation of JAK1 and JAK2. It is tempting to therefore speculate that relative levels of APS and SH2-Bbeta in a cell may titrate the cell's response to ligands that activate JAK2. Both APS and SH2-B are widely expressed. Northern blot analysis, reverse transcription-PCR, and/or Western blot analysis have revealed the presence of SH2-B transcripts and/or protein in heart, brain, lung, liver, skeletal muscle, kidney, testis, pancreas, spleen, adipose tissue, and thymus (22, 24, 27, 52) (data not shown). Using similar approaches, APS transcripts and/or protein have been detected in some of the same tissues (testis, skeletal muscle, spleen, brain, thymus, and kidney) as well as in some other tissues (prostate, uterus, peripheral leukocytes, small intestine, and bone marrow) (25, 67). Interestingly, Moodie et al. (46) detected significantly higher levels of APS transcript and protein in 3T3-L1 adipocytes than in fibroblasts. We confirmed a higher expression of APS in adipocytes compared with fibroblasts in 3T3-F442A cells, sister cells of 3T3-L1 cells. In contrast, we detected SH2-Bbeta in both 3T3-F442A fibroblasts and adipocytes (Fig. 8B) (data not shown). Further studies will be needed to delineate relative levels of APS and SH2-B in different tissues and cell types within tissues, to determine whether levels of either are subject to physiological regulation, and to determine whether relative levels of APS and SH2-Bbeta in specific cells titrate a cell's response to ligands that activate JAK2. It will also be interesting to determine whether SH2-B and APS serve similar or different adapter roles for the different JAK proteins and whether specific phosphorylated tyrosines are important for this adapter role.

    ACKNOWLEDGEMENTS

We thank Dr. Liangyou Rui for expert advice and assistance with experiments and the manuscript. We also thank Drs. J. B. Herrington, D. Gunter, and L. S. Argetsinger for many hours of helpful advice and helpful comments on the manuscript. We thank X. Wang and S. F. Archer for assistance with experiments and B. Hawkins for assistance with the manuscript. We thank Drs. J. N. Ihle and B. Witthuhn for providing JAK2 cDNA, Drs. X. Wang and C. L. Cepko for providing JAK1 cDNA, and Dr. D. D. Ginty for providing APS cDNA and alpha APS. We also thank Dr. A. C. Larner for providing alpha JAK1.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants DK34171 and DK54222.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by a predoctoral fellowship from the University of Michigan Cancer Center (National Institutes of Health Training Grant 5T32CAO96760). Student in the Cellular and Molecular Biology Graduate Program at the University of Michigan.

|| To whom correspondence should be addressed: Dept. of Physiology, University of Michigan Medical School, 6804 Medical Science II, 1301 E. Catherine St., Ann Arbor, MI 48109-0622. Tel.: 734-763-2561; Fax: 734-647-9523; E-mail: cartersu@umich.edu.

Published, JBC Papers in Press, December 18, 2001, DOI 10.1074/jbc.M109165200

2 In Fig. 2B, murine JAK1 cDNA with a C-terminal Myc tag (provided by Dr. R. D. Schreiber) was used. In Fig. 3B, murine JAK1 cDNA lacking a Myc tag (provided by Drs. X. Yang and C. L. Cepko) was used to avoid directly precipitating JAK1 with alpha Myc. The bottom band obtained using the latter cDNA (Fig. 3B, lane 2, upper panel; and lane 4) is thought to represent either a degradation product of JAK1 or a truncated form of JAK1 due to a second transcriptional start site encoded in the cDNA.

    ABBREVIATIONS

The abbreviations used are: JAK, Janus tyrosine kinase; GH, growth hormone; IFN, interferon; IL, interleukin; STATs, signal transducers and activators of transcription; PDGF, platelet-derived growth factor; alpha JAK, anti-JAK antibody; alpha Myc, anti-Myc antibody; alpha PY, anti-phosphotyrosine antibody; alpha APS, anti-APS antibody; GFP, green fluorescent protein; GHR, growth hormone receptor; DMEM, Dulbecco's modified Eagle's medium; MAPKs, mitogen-activated protein kinases; ERK, extracellular signal-regulated kinase; SOC, suppressor of cytokine signaling; EPO, erythropoietin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ihle, J. N. (1995) Adv. Immunol. 60, 1-35[Medline] [Order article via Infotrieve]
2. Smit, L. S., Meyer, D. J., Argetsinger, L. S., Schwartz, J., and Carter-Su, C. (1999) in Handbook of Physiology (Kostyo, J. L., ed), Vol. V , pp. 445-480, Oxford University Press, New York
3. Aringer, M., Cheng, A., Nelson, J. W., Chen, M., Sudarshan, C., Zhou, Y. J., and O'Shea, J. J. (1999) Life Sci. 64, 2173-2186[CrossRef][Medline] [Order article via Infotrieve]
4. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., Grosveld, G., and Ihle, J. N. (1998) Cell 93, 385-395[CrossRef][Medline] [Order article via Infotrieve]
5. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998) Cell 93, 397-409[CrossRef][Medline] [Order article via Infotrieve]
6. Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C., Yin, L., Pennica, D., Johnson, E. M., Jr., and Schreiber, R. D. (1998) Cell 93, 373-383[CrossRef][Medline] [Order article via Infotrieve]
7. Nosaka, T., van Deursen, J. M., Tripp, R. A., Thierfelder, W. E., Witthuhn, B. A., McMickle, A. P., Doherty, P. C., Grosveld, G. C., and Ihle, J. N. (1995) Science 270, 800-802[Abstract/Free Full Text]
8. Thomis, D. C., Gurniak, C. B., Tivol, E., Sharpe, A. H., and Berg, L. J. (1995) Science 270, 794-797[Abstract/Free Full Text]
9. Park, S. Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., Miyake, K., Nakauchi, H., Shirasawa, T., and Saito, T. (1995) Immunity 3, 771-782[CrossRef][Medline] [Order article via Infotrieve]
10. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., Pfeffer, K., and Muller, M. (2000) Immunity 13, 549-560[CrossRef][Medline] [Order article via Infotrieve]
11. Kishimoto, T., Taga, T., and Akira, S. (1994) Cell 76, 253-262[CrossRef][Medline] [Order article via Infotrieve]
12. Patterson, P. H., and Nawa, H. (1993) Cell 72, 123-137
13. Darnell, J. E., Jr. (1997) Science 277, 1630-1635[Abstract/Free Full Text]
14. VanderKuur, J., Allevato, G., Billestrup, N., Norstedt, G., and Carter-Su, C. (1995) J. Biol. Chem. 270, 7587-7593[Abstract/Free Full Text]
15. Argetsinger, L. S., Hsu, G. W., Myers, M. G., Jr., Billestrup, N., Norstedt, G., White, M. F., and Carter-Su, C. (1995) J. Biol. Chem. 270, 14685-14692[Abstract/Free Full Text]
16. Argetsinger, L. S., Billestrup, N., Norstedt, G., White, M. F., and Carter-Su, C. (1996) J. Biol. Chem. 271, 29415-29421[Abstract/Free Full Text]
17. Zhu, T., Goh, E. L., and Lobie, P. E. (1998) J. Biol. Chem. 273, 10682-10689[Abstract/Free Full Text]
18. Lacronique, V., Boureux, A., Valle, V. D., Poirel, H., Quang, C. T., Mauchauffe, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., and Bernard, O. A. (1997) Science 278, 1309-1312[Abstract/Free Full Text]
19. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., and Roifman, C. M. (1996) Nature 379, 645-648[CrossRef][Medline] [Order article via Infotrieve]
20. Takemoto, S., Mulloy, J. C., Cereseto, A., Migone, T. S., Patel, B. K., Matsuoka, M., Yamaguchi, K., Takatsuki, K., Kamihira, S., White, J. D., Leonard, W. J., Waldmann, T., and Franchini, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13897-13902[Abstract/Free Full Text]
21. Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A., and Jove, R. (2001) Oncogene 20, 2499-2513[CrossRef][Medline] [Order article via Infotrieve]
22. Rui, L., Mathews, L. S., Hotta, K., Gustafson, T. A., and Carter-Su, C. (1997) Mol. Cell. Biol. 17, 6633-6644[Abstract]
23. Rui, L., and Carter-Su, C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7172-7177[Abstract/Free Full Text]
24. Osborne, M. A., Dalton, S., and Kochan, J. P. (1995) Bio/Technology 13, 1474-1478[CrossRef][Medline] [Order article via Infotrieve]
25. Yokouchi, M., Suzuki, R., Masuhara, M., Komiya, S., Inoue, A., and Yoshimura, A. (1997) Oncogene 15, 7-15[CrossRef][Medline] [Order article via Infotrieve]
26. Huang, X., Li, Y., Tanaka, K., Moore, K. G., and Hayashi, J. I. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11618-11622[Abstract/Free Full Text]
27. Nelms, K., O'Neill, T. J., Li, S., Hubbard, S. R., Gustafson, T. A., and Paul, W. E. (1999) Mamm. Genome 10, 1160-1167[CrossRef][Medline] [Order article via Infotrieve]
28. Riedel, H., Wang, J., Hansen, H., and Yousaf, N. (1997) J. Biochem. (Tokyo) 122, 1105-1113[Abstract/Free Full Text]
29. Takaki, S., Sauer, K., Iritani, B. M., Chien, S., Ebihara, Y., Tsuji, K., Takatsu, K., and Perlmutter, R. M. (2000) Immunity 13, 599-609[CrossRef][Medline] [Order article via Infotrieve]
30. Yokouchi, M., Wakioka, T., Sakamoto, H., Yasukawa, H., Ohtsuka, S., Sasaki, A., Ohtsubo, M., Valius, M., Inoue, A., Komiya, S., and Yoshimura, A. (1999) Oncogene 18, 759-767[CrossRef][Medline] [Order article via Infotrieve]
31. Silvennoinen, O., Witthuhn, B., Quelle, F. W., Cleveland, J. L., Yi, T., and Ihle, J. N. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8429-8433[Abstract/Free Full Text]
32. Argetsinger, L. S., Campbell, G. S., Yang, X., Witthuhn, B. A., Silvennoinen, O., Ihle, J. N., and Carter-Su, C. (1993) Cell 74, 237-244[CrossRef][Medline] [Order article via Infotrieve]
33. David, M., Chen, H. E., Goelz, S., Larner, A. C., and Neel, B. G. (1995) Mol. Cell. Biol. 15, 7050-7058[Abstract]
34. Johnston, J. A., Kawamura, M., Kirken, R. A., Chen, Y.-Q., Blake, T. B., Shibuya, K., Ortaldo, J. R., McVicar, D. W., and O'Shea, J. J. (1994) Nature 370, 151-153[CrossRef][Medline] [Order article via Infotrieve]
35. Qian, X., Riccio, A., Zhang, Y., and Ginty, D. D. (1998) Neuron 21, 1017-1029[CrossRef][Medline] [Order article via Infotrieve]
36. Russell, S. M., Johnston, J. A., Noguchi, M., Kawamura, M., Bacon, C. M., Friedmann, M., Berg, M., McVicar, D. W., Witthuhn, B. A., Silvennoinen, O., Goldman, A. S., Schmalstieg, F. C., Ihle, J. N., OShea, J. J., and Leonard, W. J. (1994) Science 266, 1042-1045[Abstract/Free Full Text]
37. Zhou, Y. J., Hanson, E. P., Chen, Y.-Q., Magnuson, K., Chen, M., Swann, P. G., Wange, R. L., Changelian, P. S., and O'Shea, J. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13850-13855[Abstract/Free Full Text]
38. Yang, X., Chung, D., and Cepko, C. L. (1993) J. Neurosci. 13, 3006-3017[Abstract]
39. Herrington, J., Rui, L., Luo, G., Yu-, Lee, L.-y., and Carter-Su, C. (1999) J. Biol. Chem. 274, 5138-5145[Abstract/Free Full Text]
40. Emtner, M., Mathews, L. S., and Norstedt, G. (1990) Mol. Endocrinol. 4, 2014-2020[Abstract/Free Full Text]
41. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752[Abstract/Free Full Text]
42. Sumantran, V. N., Tsai, M. L., and Schwartz, J. (1992) Endocrinology 130, 2016-2024[Abstract/Free Full Text]
43. Rui, L., Gunter, D. R., Herrington, J., and Carter-Su, C. (2000) Mol. Cell. Biol. 20, 3168-3177[Abstract/Free Full Text]
44. Gouilleux, F., Wakao, H., Mundt, M., and Groner, B. (1994) EMBO J. 13, 4361-4369[Medline] [Order article via Infotrieve]
45. Ahmed, Z., Smith, B. J., Kotani, K., Wilden, P., and Pillay, T. S. (1999) Biochem. J. 341, 665-668
46. Moodie, S. A., Alleman-Sposeto, J., and Gustafson, T. A. (1999) J. Biol. Chem. 274, 11186-11193[Abstract/Free Full Text]
47. Smit, L. S., Meyer, D. J., Billestrup, N., Norstedt, G., Schwartz, J., and Carter-Su, C. (1996) Mol. Endocrinol. 10, 519-533[Abstract/Free Full Text]
48. Saharinen, P., Takaluoma, K., and Silvennoinen, O. (2000) Mol. Cell. Biol. 20, 3387-3395[Abstract/Free Full Text]
49. Ihle, J. N., and Kerr, I. M. (1995) Trends Genet. 11, 69-74[CrossRef][Medline] [Order article via Infotrieve]
50. Qian, X., and Ginty, D. D. (2001) Mol. Cell. Biol. 21, 1613-1620[Abstract/Free Full Text]
51. Rui, L., and Carter-Su, C. (1998) J. Biol. Chem. 273, 21239-21245[Abstract/Free Full Text]
52. Kotani, K., Wilden, P., and Pillay, T. S. (1998) Biochem. J. 335, 103-109
53. Rui, L., Herrington, J. B., and Carter-Su, C. (1999) J. Biol. Chem. 274, 10590-10594[Abstract/Free Full Text]
54. Rui, L., Herrington, J., and Carter-Su, C. (1999) J. Biol. Chem. 274, 26485-26492[Abstract/Free Full Text]
55. Witthuhn, B. A., Williams, M. D., Kerawalla, H., and Uckun, F. M. (1999) Leuk. Lymphoma 32, 289-297[Medline] [Order article via Infotrieve]
56. Bergad, P. L., Shih, H.-M., Towle, H. C., Schwarzenberg, S. J., and Berry, S. A. (1995) J. Biol. Chem. 270, 24903-24910[Abstract/Free Full Text]
57. Galsgaard, E. D., Gouilleux, F., Groner, B., Serup, P., Nielsen, J. H., and Billestrup, N. (1996) Mol. Endocrin. 10, 652-660[Abstract/Free Full Text]
58. Hansen, L. H., Wang, X., Kopchick, J. J., Bouchelouche, P., Nielsen, J. H., Galsgaard, E. D., and Billestrup, N. (1996) J. Biol. Chem. 271, 12669-12673[Abstract/Free Full Text]
59. Subramanian, A., Teixeira, J., Wang, J., and Gil, G. (1995) Mol. Cell. Biol. 15, 4672-4682[Abstract]
60. Wood, T. J., Sliva, D., Lobie, P. E., Pircher, T. J., Gouilleux, F., Wakao, H., Gustafsson, J. A., Groner, B., Norstedt, G., and Haldosen, L. A. (1995) J. Biol. Chem. 270, 9448-9453[Abstract/Free Full Text]
61. Ooi, G. T., Cohen, F. J., Tseng, L. Y., Rechler, M. M., and Boisclair, Y. R. (1997) Mol. Endocrinol. 11, 997-1007[Abstract/Free Full Text]
62. Meton, I., Boot, E. P., Sussenbach, J. S., and Steenbergh, P. H. (1999) FEBS Lett. 444, 155-159[CrossRef][Medline] [Order article via Infotrieve]
63. Benbassat, C., Shoba, L. N., Newman, M., Adamo, M. L., Frank, S. J., and Lowe, W. L., Jr. (1999) Endocrinology 140, 3073-3081[Abstract/Free Full Text]
64. Wakioka, T., Sasaki, A., Mitsui, K., Yokouchi, M., Inoue, A., Komiya, S., and Yoshimura, A. (1999) Leukemia (Baltimore) 13, 760-767[CrossRef][Medline] [Order article via Infotrieve]
65. Ahmed, Z., Smith, B. J., and Pillay, T. S. (2000) FEBS Lett. 475, 31-34[CrossRef][Medline] [Order article via Infotrieve]
66. Thien, C. B., and Langdon, W. Y. (2001) Nat. Rev. Mol. Cell. Biol. 2, 294-307[CrossRef][Medline] [Order article via Infotrieve]
67. Iseki, M., Takaki, S., and Takatsu, K. (2000) Biochem. Biophys. Res. Commun. 272, 45-54[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
M. Li, Z. Li, D. L. Morris, and L. Rui
Identification of SH2B2{beta} as an Inhibitor for SH2B1- and SH2B2{alpha}-Promoted Janus Kinase-2 Activation and Insulin Signaling
Endocrinology, April 1, 2007; 148(4): 1615 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. H. Kurzer, P. Saharinen, O. Silvennoinen, and C. Carter-Su
Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State.
Mol. Cell. Biol., September 1, 2006; 26(17): 6381 - 6394.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Li, D. Ren, M. Iseki, S. Takaki, and L. Rui
Differential Role of SH2-B and APS in Regulating Energy and Glucose Homeostasis
Endocrinology, May 1, 2006; 147(5): 2163 - 2170.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. H. Kurzer, L. S. Argetsinger, Y.-J. Zhou, J.-L. K. Kouadio, J. J. O'Shea, and C. Carter-Su
Tyrosine 813 Is a Site of JAK2 Autophosphorylation Critical for Activation of JAK2 by SH2-B{beta}
Mol. Cell. Biol., May 15, 2004; 24(10): 4557 - 4570.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
P. Saharinen, M. Vihinen, and O. Silvennoinen
Autoinhibition of Jak2 Tyrosine Kinase Is Dependent on Specific Regions in Its Pseudokinase Domain
Mol. Biol. Cell, April 1, 2003; 14(4): 1448 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. B. O'Brien, L. S. Argetsinger, M. Diakonova, and C. Carter-Su
YXXL Motifs in SH2-Bbeta Are Phosphorylated by JAK2, JAK1, and Platelet-derived Growth Factor Receptor and Are Required for Membrane Ruffling
J. Biol. Chem., March 28, 2003; 278(14): 11970 - 11978.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Takaki, Y. Tezuka, K. Sauer, C. Kubo, S.-M. Kwon, E. Armstead, K. Nakao, M. Katsuki, R. M. Perlmutter, and K. Takatsu
Impaired Lymphopoiesis and Altered B Cell Subpopulations in Mice Overexpressing Lnk Adaptor Protein
J. Immunol., January 15, 2003; 170(2): 703 - 710.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/10/8673    most recent
M109165200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, K. B.
Right arrow Articles by Carter-Su, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, K. B.
Right arrow Articles by Carter-Su, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement